Teva Pharmaceutical Industries Ltd
TEVA- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0000818686
In the last 90 days, Teva Pharmaceutical Industries Ltd insiders filed 0 open-market purchases and 8 sales; 675 institutions reported holding it in 13F filings for Q2 2026, worth $24.8B in total; 3 superinvestors hold it, including Greenlight Capital and Duquesne Family Office.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $17.0M in total
- 8
- 13F holdersQ2 2026, +28 vs. previous quarter
- 675
- 13F valueReported value at the end of Q2 2026
- $24.8B
- Superinvestors holdingAt the end of Q2 2026
- 3
Price chart
Superinvestors holding TEVA, Q2 2026
3 superinvestors report holding Teva Pharmaceutical Industries Ltd on Form 13F. Percentages are the stock's share of each portfolio.
Greenlight Capital
David Einhorn
2.5%
Teva Pharmaceutical Industries Ltd's share of the portfolio
- Shares
- 2,886,059
- Value
- $97.8M
Duquesne Family Office
Stanley Druckenmiller
0.5%
Teva Pharmaceutical Industries Ltd's share of the portfolio
- Shares
- 624,999
- Value
- $21.2M
| Superinvestor | Weight | Value |
|---|---|---|
| ARK Invest | <0.1% | $2.33M |
Latest insider trades
Open-market purchases and sales by Teva Pharmaceutical Industries Ltd insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 22, 2026 (view filing)5:01 PM ET | Sep 18 | 4 days | Savage BrianInterim Chief Legal Officer | SSale | −7.34K | $38.85 | −$285.2K | −46.3%8.50K after | 3 lots |
| Sep 22, 2026 (view filing)4:21 PM ET | Sep 18 | 4 days | Mignone RobertoDirector | SSale | −367.6K | $39.06 | −$14.4M | −100.0%0 after | |
| Aug 25, 2026 (view filing)4:05 PM ET | Aug 21 | 4 days | Weiss AmirChief Accounting Officer | SSale | −9.45K | $37.62 | −$355.3K | −41.9%13.1K after | 2 lots |
| Aug 25, 2026 (view filing)4:03 PM ET | Aug 21 | 4 days | Satchi-Fainaro RonitDirector | SSale | −415 | $37.25 | −$15.5K | −0.4%112.0K after | |
| Aug 19, 2026 (view filing)4:00 PM ET | Aug 17 | 2 days | Lippman EvanEVP, Business Development | SSale | −18.6K | $36.57 | −$680.3K | −42.1%25.6K after | 10b5-1 |
| Aug 10, 2026 (view filing)6:07 AM ET | Aug 5 | 5 daysLate | Zaks Tal ZviDirector | SSale | −17 | $34.87 | −$592.71 | 0.0%73.2K after | |
| Aug 5, 2026 (view filing)4:04 PM ET | Aug 3 | 2 days | Jover PlacidSee "Remarks" | SSale | −12.8K | $34.88 | −$447.4K | −65.4%6.77K after | 10b5-1 |
| Aug 5, 2026 (view filing)4:02 PM ET | Aug 3 | 2 days | Hughes Eric ASee "Remarks" | SSale | −25.6K | $34.88 | −$892.1K | −15.9%134.9K after | 10b5-1 |
| Jun 22, 2026 (view filing) | Jun 18 | 4 days | Shields MatthewEVP, Global Operations | SSale | −9.99K | $32.19 | −$321.5K | −100.0%0 after | |
| Jun 16, 2026 (view filing) | Jun 11 | 5 daysLate | Kalif Eliyahu SharonEVP, Chief Financial Officer | SSale | −106.6K | $34.10 | −$3.63M | −61.9%65.6K after | 10b5-1 |
Top 10 13F holders, Q2 2026
The largest institutional positions in Teva Pharmaceutical Industries Ltd at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| BlackRock, Inc. | 63,894,301 | $2.16B | 0.03% | −1,242,163−1.9% | Reduced |
| Harel Insurance Investments & Financial Services Ltd. | 48,138,805 | $1.63B | 7.93% | +2,182,091+4.7% | Added |
| Phoenix Holdings Ltd. | 42,933,367 | $1.45B | 9.94% | +155,953+0.4% | Added |
| WCM Investment Management, LLC | 41,315,232 | $1.38B | 2.49% | +494,632+1.2% | Added |
| Clal Insurance Enterprises Holdings Ltd | 40,596,506 | $1.37B | 6.15% | +2,150,000+5.6% | Added |
| Menora Mivtachim Holdings Ltd. | 39,854,383 | $1.35B | 5.27% | +228,000+0.6% | Added |
| Migdal Insurance & Financial Holdings Ltd. | 38,922,212 | $1.32B | 8.44% | +1,020,000+2.7% | Added |
| Norges Bank | 32,299,753 | $1.09B | 0.11% | +32,299,753 | New |
| FMR LLC | 30,258,016 | $1.03B | 0.04% | −2,874,779−8.7% | Reduced |
| Exor Capital LLP | 20,205,943 | $684.6M | 14.73% | −7,564,914−27.2% | Reduced |